title: Effects of intravenous infusion of lipid-free apo A-I in humans.
abstract: Apolipoprotein (apo) A-I is the principal protein component of the plasma high density lipoproteins (HDLs). Tissue culture studies have suggested that lipid-free apo A-I may, by recruiting phospholipids (PLs) and unesterified cholesterol from cell membranes, initiate reverse cholesterol transport and provide a nidus for the formation, via lipid-poor, pre-beta-migrating HDLs, of spheroidal alpha-migrating HDLs. Apo A-I has also been shown to inhibit hepatic lipase (HL) and lipoprotein lipase (LPL) in vitro. To further study its functions and fate in vivo, we gave lipid-free apo A-I intravenously on a total of 32 occasions to six men with low HDL cholesterol (30 to 38 mg/dL) by bolus injection (25 mg/kg) and/or by infusion over 5 hours (1.25, 2.5, 5.0, and 10.0 mg.kg-1.h-1). The procedure was well tolerated: there were no clinical, biochemical, or hematologic changes, and there was no evidence of allergic, immunologic, or acute-phase responses. The 5-hour infusions increased plasma total apo A-I concentration in a dose-related manner by 10 to 50 mg/dL after which it decreased, with a half-life of 15 to 54 hours. Coinfusion of Intralipid reduced the clearance rate. The apparent volume of distribution exceeded the known extracellular space in humans, suggesting extensive first-pass clearance by one or more organs. No apo A-I appeared in the urine. Increases in apo A-I mass were confined to the pre-beta region on crossed immunoelectrophoresis of plasma and to HDL-size particles on size exclusion chromatography. Increases were recorded in HDL PL, but not in HDL unesterified or esterified cholesterol. Increases also occurred in LDL PL and in very low density lipoprotein cholesterol, triglycerides, and PL but not in plasma total apo B concentration. These results can all be explained by combined inhibition of HL and LPL activities. Owing to the effects that this would have had on HDL metabolism, no conclusions can be drawn from these data about the role of lipid-free apo A-I in the removal of PL and cholesterol from peripheral tissues in humans. The kinetic data suggest that the fractional catabolic rate of lipid-free apo A-I exceeds that of spheroidal HDLs and is reduced in the presence of surplus PL.
authors.affiliation: Department of Cardiovascular Biochemistry, St Bartholomew's Hospital Medical College, London, UK.
authors.forename: M N
authors.initials: MN
authors.lastname: Nanjee
authors.forename: J R
authors.initials: JR
authors.lastname: Crouse
authors.forename: J M
authors.initials: JM
authors.lastname: King
authors.forename: R
authors.initials: R
authors.lastname: Hovorka
authors.forename: S E
authors.initials: SE
authors.lastname: Rees
authors.forename: E R
authors.initials: ER
authors.lastname: Carson
authors.forename: J J
authors.initials: JJ
authors.lastname: Morgenthaler
authors.forename: P
authors.initials: P
authors.lastname: Lerch
authors.forename: N E
authors.initials: NE
authors.lastname: Miller
mesh_terms: D000368:Aged; D016632:Apolipoprotein A-I / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D016632:Apolipoprotein A-I; D008075:Lipoproteins, HDL